

---

# Hepatic Resection *Versus* Transplantation for Hepatocellular Carcinoma

---

SHUNZABURO IWATSUKI, M.D.,\* THOMAS E. STARZL, M.D., Ph.D.,\* DANIEL G. SHEAHAN, M.B., M.Sc.,†  
ITSUO YOKOYAMA, M.D.,\* ANTHONY J. DEMETRIS, M.D.,† SATURO TODO, M.D.,\* ANDREAS G. TZAKIS, M.D.,\*  
DAVID H. VAN THIEL, M.D.,\* BRIAN CARR, M.D., Ph.D.,\* RICHARD SELBY, M.D.,\* and JUAN MADARIAGA, M.D.\*

---

During the 10-year period (1980 to 1989), 76 patients with hepatocellular carcinoma (HCC) were treated by subtotal hepatic resection (HX) and 105 patients by orthotopic liver transplantation (TX) under cyclosporine-steroid therapy. Overall 1- to 5-year survival rates of the HX group were 71.1%, 55.0%, 47.2%, 37.2%, and 32.9%, respectively, and those of the TX group were 65.7%, 49.0%, 39.2%, 35.6%, and 35.6%, respectively. The survival rates after HX and after TX correlated well with pTNM stages and were similar in each stage between the two groups. However, when HCC was associated with cirrhosis of the liver, the survival rates after TX were significantly better than those after HX at each stage of pTNM classification. The tumor-recurrence rate was high both after HX (50%) and TX (43%), particularly in advanced stages of pTNM classification (60% or more). Twelve patients after HX and 13 patients after TX lived more than 5 years during this 10-year period. Fibrolamellar HCC and early stages of HCC were highly represented among the long-term survivors. Further improvement in survival rates depends on nonsurgical anti-cancer therapy before and/or after surgical removal of HCC.

**L**IVER TRANSPLANTATION HAS been widely accepted as a useful therapy for various advanced liver diseases.<sup>1-3</sup> However its role in the treatment of hepatobiliary malignancy still remains to be determined.<sup>4-15</sup> Our earlier reports<sup>4-7</sup> and those of others<sup>8-11</sup> have emphasized the high recurrence rate of hepatocellular carcinoma (HCC) in patients treated with liver transplantation, but they also recognized a handful of patients who were apparently cured of their malignancy by hepatic re-

*From the Departments of Surgery\* and Pathology,† University of Pittsburgh School of Medicine and the Veterans Administration Medical Center, Pittsburgh, Pennsylvania*

---

placement. The same is true with conventional subtotal hepatic resection.<sup>16-30</sup>

In this study we compared the results obtained by liver transplantation to those achieved by subtotal hepatic resection among our own series of 181 patients with HCC according to the pTNM staging. The prognostic factors other than those included in pTNM staging were also examined for their significance.

## Materials and Methods

During the 10-year period between 1980 and 1989, 76 patients with HCC were treated by subtotal hepatic resection (HX) and additional 105 patients by orthotopic liver transplantation (TX) under cyclosporine-steroid immunosuppressive therapy at the University of Colorado Health Sciences Center (1980), and at the University Health Center of Pittsburgh (1981 to 1989).

Liver transplantation was used if subtotal hepatic resection was not anatomically feasible due to extensive intrahepatic involvement of malignancy, or if the underlying liver disease and/or hepatic failure precluded this possibility. One third of the patients in the transplant group had anatomically unresectable HCC in the normal liver, one third had functionally unresectable HCC in the cirrhotic liver, and one third had misdiagnosed HCC in the failing liver. The extent of HCC was staged using the pTNM classification proposed by the International Union Against Cancer and the American Joint Committee on Cancer (Table 1).<sup>31,32</sup>

---

Presented at the 111th Annual Meeting of the American Surgical Association, April 11-13, 1991, Boca Raton, Florida.

Supported by research grants from the Veterans Administration and Project Grant DK 29961 from the National Institutes of Health, Bethesda, Maryland.

Address reprint requests to Shunzaburo Iwatsuki, M.D., Department of Surgery, 3601 Fifth Ave., Falk Clinic 5C, Pittsburgh, PA 15213.

Accepted for publication April 22, 1991.

TABLE 1. pTNM Pathologic Classifications

Classification			
Stage I	T1	N0	M0
Stage II	T2	N0	M0
Stage III	T1	N1	M0
	T2	N1	M0
	T3	N0, N1	M0
Stage IVA	T4	Any N	M0
Stage IVB	Any T	Any N	M1

T1: Solitary,  $\leq 2$  cm, without vascular invasion.

T2: Solitary,  $\leq 2$  cm, with vascular invasion.

Multiple, one lobe,  $\leq 2$  cm, without vascular invasion.

Solitary,  $> 2$  cm, without vascular invasion.

T3: Solitary,  $> 2$  cm, with vascular invasion.

Multiple, one lobe,  $> 2$  cm, with or without vascular invasion.

T4: Multiple,  $> 1$  lobe.

Invasion of major branch of portal or hepatic veins.

N1: Regional

M1: Distant metastasis.

#### Subtotal Hepatic Resection Group (HX Group)

There were 76 patients in this group; 53 were male and 23 were female. The ages ranged from 9 to 86 years with a mean  $\pm$  standard deviation (SD) of  $51.4 \pm 17.4$  years. Seventeen of seventy-six patients had associated cirrhosis of the liver. Eight patients were chronic carriers of hepatitis B surface antigen (HBsAg), and three others had hepatitis B surface antibody and/or core antibody (HBsAb and/or HBcAb).

These 76 patients with HCC were stratified according to the pTNM classification and are shown in Table 2. Twelve of seventy-six HCCs were those of fibrolamellar variant (FL-HCC).

The follow-up periods of this group of patients ranged from 16 to 131 months, with a median follow-up of 53 months as of February 1, 1991.

#### Liver Transplantation Group (TX Group)

There were 105 patients in this group; 70 were male and 35 were female. The ages ranged from 3 to 69 years, with a mean  $\pm$  SD of  $43.5 \pm 18.2$  years. Seventy-one of

TABLE 2. pTNM Stages of 76 Patients with Hepatocellular Carcinoma Treated by Subtotal Hepatic Resection

pTNM Stage	Number of Patients	Number of Patients	
	Total HCC	Non-FL	FL
I	0	0	0
II	19	16	3
III	25	18	7
IV-A	32	30	2
Total	76	64	12

HCC, hepatocellular carcinoma; FL, fibrolamellar HCC.

one hundred five patients had associated cirrhosis of the liver. Twenty-three patients were chronic carriers of HBsAg and 11 others had HBsAb and/or HBcAb.

These 105 patients with HCC were stratified according to the pTNM classification and are shown in Table 3. Ten of one hundred five patients had FL-HCC.

The follow-up periods of this group of patients ranged from 16 to 131 months, with a median follow-up of 37 months as of February 1, 1991.

#### Prognostic Factors

The variables included in pTNM classification (Table 1) were examined individually for their influence on survival rates before grouping into the stages. Other variables examined were (1) associated cirrhosis, (2) HBsAg, (3) microscopic tumor margin, (4) shape of the tumor(s) (circumscribed *versus* infiltrative), and (5) fibrolamellar variant. All variables examined are listed in Table 7.

#### Statistical Analysis

Actuarial survival rates were calculated by the life-table method using the BMDP statistical software (University of California Press, Berkeley, CA). Statistical comparisons across different groups were made by the method of Mantel-Cox for univariate analysis. The Cox proportional hazards regression model was used to assess the relative prognostic importance of factors in predicting survival (multivariate analysis). Differences were considered significant if the probability value was less than 0.05.

## Results

#### Survival Rates

Overall survival rates of the subtotal hepatic resection group (HX group) and those of the liver transplantation group (TX group) are shown in Figure 1 and Tables 4 and 5. There was no difference in the survival rates between the two groups.

In the HX group the survival rates of patients with FL-HCC were significantly ( $p = 0.016$ ) higher than those of

TABLE 3. pTNM Stages of 105 Patients with Hepatocellular Carcinoma Treated by Liver Transplantation

pTNM Stage	Number of Patients	Number of Patients	
	Total HCC	Non-FL	FL
I	4	4	0
II	19	17	2
III	23	23	0
IV-A	59	51	8
Total	105	95	10

HCC, hepatocellular carcinoma; FL, fibrolamellar HCC.




FIG. 1. Overall survival rates of patients with hepatocellular carcinoma. HX, subtotal hepatic resection; TX, liver transplantation.

patients with nonfibrolamellar hepatocellular carcinoma (non-FL-HCC) (Table 4). In the TX group, however, the survival rates were quite similar between them (Table 5) because 8 of the 10 patients were in stage IV-A (Table 3). The survival rates of patients with FL-HCC tended to be higher in the HX group than in the TX group, but the difference was not statistically significant (Tables 4 and 5).

When HCC was associated with cirrhosis of the liver, the survival rates were significantly ( $p = 0.001$ ) lower than

those without cirrhosis in the HX group (Table 4), but the survival rates were similar in the TX group (Table 5). The survival rates of the HX group were significantly ( $p = 0.02$ ) lower than those of the TX group when HCC was associated with cirrhosis of the liver, but they were similar when HCC was not associated with cirrhosis (Tables 4 and 5). There was no 4-year survivor after subtotal hepatic resection (HX) among the patients with HCC in the cirrhotic liver, but the 5-year survival rate after transplantation (TX) was 40.7%.

The overall survival rates were stratified by the pTNM stages and are shown in Tables 4 and 5. Both in the HX group and in the TX group the pTNM stages correlated well with the survival rates. In both groups the survival rates of stage IV-A patients were significantly ( $p < 0.05$ ) lower than those of other stages. There was no statistically significant difference in the survival rates when they were compared in the same pTNM stages between the HX group and the TX group (Table 4 and 5). However, when the survival rates of patients with HCC in the cirrhotic liver were compared in the same stages, the survival rates of the TX group were significantly ( $p < 0.05$ ) better than those of the HX group (Table 6). The difference was most striking in stage III.

#### Prognostic Factors

Univariate analyses of five factors included in the pTNM classification and six others were performed by the Mantel-Cox test and the results were summarized in Table 7, with mean survival rates in months. The poor prognostic factors of statistical significance both in the

TABLE 4. Survival Rates After Subtotal Hepatic Resection for Hepatocellular Carcinoma

	3 months	6 months	1 year	2 years	3 years	4 years	5 years
Total HCC (n = 76)	82.9% (63)	77.6% (59)	71.1% (54)	55.0% (36)	47.2% (26)	37.2% (17)	32.9% (12)
FL-HCC (n = 12)	100% (12)	100% (12)	100% (12)	83.3% (9)	83.3% (9)	64.8% (6)	64.8% (5)
Non-FL-HCC (n = 64)	79.7% (51)	73.4% (47)	65.6% (42)	49.7% (27)	40.2% (17)	32.1% (11)	26.3% (7)
Cirrhosis (n = 17)	64.7% (11)	47.1% (8)	35.3% (6)	23.5% (4)	5.9% (1)	0 (0)	— —
Noncirrhosis (n = 59)	88.1% (52)	86.4% (51)	81.4% (48)	64.3% (32)	60.2% (25)	49.5% (17)	43.7% (12)
TNM Stage I (n = 0)							
TNM Stage II (n = 19)	100% (18)	100% (18)	100% (18)	84.2% (15)	78.6% (13)	58.2% (8)	43.7% (4)
TNM Stage III (n = 25)	80.0% (20)	80.0% (20)	76.0% (19)	68.0% (14)	53.4% (9)	46.8% (6)	46.8% (5)
TNM Stage IV-A (n = 32)	78.1% (25)	65.6% (21)	53.1% (17)	26.9% (7)	22.4% (4)	16.8% (3)	16.8% (3)

TABLE 5. Survival Rates After Liver Transplantation for Hepatocellular Carcinoma

	3 months	6 months	1 year	2 years	3 years	4 years	5 years
Total HCC (n = 105)	85.7% (90)	74.3% (78)	65.7% (69)	49.0% (45)	39.2% (26)	35.6% (16)	35.6% (13)
FL-HCC (n = 10)	90.0% (9)	90.0% (9)	80.0% (8)	70.0% (2)	50.0% (4)	37.5% (3)	37.5% (3)
Non-FL-HCC (n = 95)	85.3% (81)	72.6% (69)	64.2% (61)	46.8% (38)	38.3% (22)	36.5% (13)	36.5% (10)
Cirrhosis (n = 71)	84.5% (60)	71.8% (51)	63.4% (45)	48.6% (28)	42.9% (21)	40.7% (12)	40.7% (10)
Noncirrhosis (n = 34)	88.2% (30)	79.4% (27)	70.6% (24)	50.0% (16)	32.5% (6)	26.0% (4)	26.0% (3)
TNM Stage I (n = 4)	75.0% (3)	75.0% (3)	75.0% (3)	75.0% (3)	75.0% (2)	75.0% (2)	75.0% (2)
TNM Stage II (n = 19)	84.2% (16)	84.2% (16)	79.0% (15)	68.4% (12)	68.4% (12)	68.4% (8)	68.4% (5)
TNM Stage III (n = 23)	87.0% (20)	78.3% (18)	78.3% (18)	59.8% (11)	59.8% (8)	52.3% (4)	52.3% (4)
TNM Stage IV-A (n = 59)	86.4% (51)	69.5% (41)	55.9% (33)	36.6% (15)	16.3% (4)	10.9% (2)	10.9% (2)

HX group and in the TX group were (1) multiple gross tumors, (2) vascular invasion, (3) advanced pTNM stages, (4) positive surgical margin, and (5) infiltrative shape of tumor.

The tumor size of more than 2 cm was a significantly poor prognostic factor in the TX group, but it could not be examined in the HX group because there was no tumor measuring 2 cm or less in this group. Bilobar involvement

of tumor and lymph node metastasis were significantly poor prognostic factors in the TX group, but they were not significant in the HX group. Fibrolamellar histology was a significantly good prognostic factor in the HX group. The fibrolamellar patients had a higher survival rate in the TX group for the first 3 years, but this factor was not statistically significant because 8 of the 10 patients with this tumor were classified as stage IV-A. Associated cir-

TABLE 6. Survival of Patients with Hepatocellular Carcinoma in the Cirrhotic Liver

	3 months	6 months	1 year	2 years	3 years	4 years	5 years
<b>HX Group</b>							
Stage I (n = 0)							
Stage II (n = 2)	100% (2)	100% (2)	100% (2)	50.0% (1)	50.0% (1)	0% (0)	
Stage III (n = 5)	60.0% (3)	60.0% (3)	40.0% (2)	40.0% (2)	0% (0)		
Stage IV-A (n = 10)	60.0% (6)	30.0% (3)	20.0% (2)	0% (0)			
<b>TX Group</b>							
Stage I (n = 4)	75.0% (3)	75.0% (3)	75.0% (3)	75.0% (3)	75.0% (2)	75.0% (2)	75.0% (2)
Stage II (n = 16)	81.3% (13)	81.3% (13)	81.3% (13)	75.0% (11)	75.0% (11)	75.0% (7)	75.0% (5)
Stage III (n = 19)	89.5% (17)	79.0% (15)	79.0% (15)	56.1% (8)	56.1% (7)	48.1% (3)	48.1% (3)
Stage IV-A (n = 32)	84.4% (27)	62.5% (20)	43.8% (14)	26.2% (6)	0% (0)		

TABLE 7. Univariate Analysis of Prognostic Factors (Mean Survival in Months [ $\pm$  SE])

Factor	Subtotal Hepatic Resection	Liver Transplantation
Size of Tumor		p = 0.0241
$\leq 2$ cm	(n = 0)	76.4 $\pm$ 14.8 (n = 12)
>2 cm	51.7 $\pm$ 6.6 (n = 76)	40.4 $\pm$ 5.2 (n = 93)
Number of Gross Tumor	p = 0.0004	p = 0.0143
Single	65.5 $\pm$ 8.5 (n = 46)	68.6 $\pm$ 10.3 (n = 29)
Multiple	25.1 $\pm$ 6.1 (n = 30)	37.9 $\pm$ 5.5 (n = 76)
Lobar Involvement	p = 0.2916	p = 0.0003
Unilobar	41.3 $\pm$ 7.8 (n = 44)	66.1 $\pm$ 7.8 (n = 51)
Bilobar	60.2 $\pm$ 9.7 (n = 32)*	28.0 $\pm$ 5.2 (n = 54)
Vascular Invasion	p = 0.0000	p = 0.0002
None (V0)	67.1 $\pm$ 11.6 (n = 24)	73.2 $\pm$ 10.1 (n = 30)
Microscopic (V1)	51.8 $\pm$ 9.7 (n = 30)	43.3 $\pm$ 7.1 (n = 37)
Macroscopic (V2)	28.1 $\pm$ 9.2 (n = 22)	21.6 $\pm$ 5.6 (n = 38)
Lymph Node Metastasis	p = 0.6188	p = 0.0054
Absent (N0)	52.7 $\pm$ 6.8 (n = 72)	49.7 $\pm$ 5.4 (n = 96)
Present (N1)	28.0 $\pm$ 7.2 (n = 4)*	10.5 $\pm$ 3.7 (n = 9)
pTNM Stage	p = 0.0069	p = 0.0015
I	(n = 0)	81.1 $\pm$ 23.2 (n = 4)
II	64.0 $\pm$ 12.6 (n = 19)	70.0 $\pm$ 13.2 (n = 19)
III	57.0 $\pm$ 10.6 (n = 25)	53.7 $\pm$ 9.6 (n = 23)
IV-A	34.0 $\pm$ 8.7 (n = 32)	26.5 $\pm$ 5.3 (n = 59)
Histological Type	p = 0.0277	p = 0.7023
Fibrolamellar	84.9 $\pm$ 15.8 (n = 12)	51.4 $\pm$ 14.4 (n = 10)
Nonfibrolamellar	42.9 $\pm$ 6.5 (n = 64)	47.5 $\pm$ 5.5 (n = 95)
Associated Cirrhosis	p = 0.0000	p = 0.6450
Present	11.4 $\pm$ 3.0 (n = 17)*	50.0 $\pm$ 6.4 (n = 71)
Absent	64.6 $\pm$ 7.9 (n = 59)	39.0 $\pm$ 7.6 (n = 34)
Microscopic Margin	p = 0.0293	p = 0.0042
Positive	29.3 $\pm$ 11.2 (n = 14)*	10.7 $\pm$ 3.9 (n = 9)
Negative	57.7 $\pm$ 7.6 (n = 62)	49.9 $\pm$ 5.5 (n = 96)
HBsAg	p = 0.0097	p = 0.3183
Positive	17.1 $\pm$ 6.8 (n = 8)	30.4 $\pm$ 6.3 (n = 23)
Negative	56.9 $\pm$ 7.2 (n = 68)	49.6 $\pm$ 5.9 (n = 82)
Size of Uninodular Tumor	p = 0.1423	p = 0.0034
$\leq 5$ cm	26.0 $\pm$ 7.2 (n = 6)*	89.6 $\pm$ 12.4 (n = 18)
>5 cm	69.4 $\pm$ 9.1 (n = 40)*	28.1 $\pm$ 9.8 (n = 11)
Shape of Tumor	p = 0.0000	p = 0.0010
Circumscribed	63.1 $\pm$ 8.0 (n = 58)	57.2 $\pm$ 6.4 (n = 70)
Infiltrative	17.3 $\pm$ 5.4 (n = 18)	21.8 $\pm$ 7.5 (n = 32)

\* The difference between the HX group and the TX group is statistically significant ( $p < 0.05$ ).

SE, standard error.

rhosis of the liver and chronic HBsAg carrier status were significantly poor prognostic factors in the HX group but they were not significant in the TX group.

Multivariate analysis of prognostic factors that reached statistical significance in univariate analysis ( $p < 0.05$ ) revealed that associated cirrhosis and infiltrative shape of tumor were independently significant factors of poor survival in the HX group. In the TX group, bilobar involvement, microscopically positive tumor margin, lymph node metastasis, and vascular invasion were independently associated with poor survival rates.

### Tumor Recurrence and Cause of Death

The recurrence of HCC was confirmed in 38 (50%) of the 76 patients in the HX group and in 45 (42.9%) of the 105 patients in the TX group during the follow-up period. Although overall incidence of tumor recurrence was similar for the HX group and the TX group, the HCCs of stages II and III recurred more frequently ( $p = 0.003$ ) in the HX group than in the TX group (Table 8). The incidence of tumor recurrence in stage IV-A was extremely high: 59.4% in the HX group and 67.8% in the TX group.

Forty-eight (63.2%) of the 76 patients in the HX group and 67 (63.8%) of the 105 patients in the TX group died during the follow-up period. Approximately two thirds of deaths were directly or indirectly related to the tumor recurrence, both in the HX group and the TX group. It is worth noting that tumor-related death among patients with HCC of stages II and III was significantly ( $p = 0.013$ ) more frequent in the HX group than in Tx group (Table 8). Tumor-related death was quite frequent among patients with stage IV-A tumor both in the HX group (53.1%) and the TX group (64.4%) (Table 8).

Approximately one fifth of the patients in the HX group and in the TX group died of various complications of hepatic resection or transplantation that were not related to tumor recurrence (Table 8).

#### Five-year Survivors

There were 25 patients who survived for 5 years: 12 in the HX group and 13 in the TX group (Table 9). None of the twelve 5-year survivors in the HX group had associated cirrhosis of the liver, but 10 of the 13 5-year survivors in the TX group had HCCs that developed in the cirrhotic liver. Five of the twelve patients in the HX group and 3 of the 13 patients in the TX group had FL-HCC, which was highly represented among the long-term survivors.

Of the 25 patients surviving 5 years, 2 patients had stage I tumors, 9 patients each had stage II or stage III tumors, and 5 patients had stage IV-A tumors. Three of the five patients with stage IV-A tumors had FL-HCC and the remaining two patients had nonfibrolamellar HCC, both of whom were in the HX group. There was no 5-year survivor in the TX group who had nonfibrolamellar HCC (non-FL-HCC) of stage IV-A disease.

## Discussion

The results of various therapies for HCC have rarely been reported using a universal staging system such as the TNM classification.<sup>11,14,33</sup> Thus the sensible comparisons of results among various therapies and among different reports have been very difficult. To compare our results of subtotal hepatic resection for HCC to those of liver transplantation, our patients were stratified according to their pTNM stage.<sup>31,32</sup> As shown in Tables 4 to 7, the pTNM staging has proved useful in predicting the survival rates after hepatic resection ( $p = 0.0069$ ) and liver transplantation ( $p = 0.0015$ ). Although all of the variables included in the TNM staging are significant prognostic factors (Table 7), the multivariate analysis of these factors among our patients revealed that macroscopic vascular invasion, lymph node metastasis, and bilobar distribution of the tumor(s) were independently significant among them in predicting the survival rates.

The factors other than those included in the TNM classification were also valuable in predicting prognosis of HCC (Table 7) as reported by others.<sup>18-30</sup> Our study confirms that associated cirrhosis of the liver and infiltrative shape of the tumor were independently significant in predicting the poor survival rates after subtotal hepatic resection and liver transplantation. Although the survival rates of patients with HCC were significantly lower than those without malignancy after liver transplantation,<sup>1-11</sup> they were quite similar to those after subtotal hepatic resection in each stage of the pTNM classification (Tables 4 and 5). However, when the patients had HCC in the cirrhotic liver, the survival rates after liver transplantation were significantly higher than those after subtotal hepatic resection in each stage (Table 6).

Our overall survival rates after subtotal hepatic resection for HCC (67.1% at 1 year, 47.2% at 3 years, and 32.9%

TABLE 8. Tumor Recurrence and Causes of Death

	Number of Patients		
	Recurrence of Tumor	Death With Tumor	Death Without Tumor
<b>HX Group</b>			
Stage II (n = 19)	10 (52.6%)	8 (42.1%)	2 (10.5%)
Stage III (n = 25)	9 (36.0%)	7 (28.0%)	6 (24.0%)
Stage IV-A (n = 32)	19 (59.4%)	17 (53.1%)	7 (21.9%)
Total (n = 76)	38 (50.0%)	32 (42.1%)	15 (19.7%)
<b>TX Group</b>			
Stage I (n = 4)	0 (0%)	0 (0%)	1 (25.0%)
Stage II (n = 19)	1 (5.3%)	1 (5.3%)	6 (31.6%)
Stage III (n = 23)	4 (17.4%)	3 (13.0%)	8 (24.8%)
Stage IV-A (n = 59)	40 (67.8%)	38 (64.4%)	10 (16.9%)
Total (n = 105)	45 (42.9%)	42 (40%)	25 (23.8%)

TABLE 9. List of 25 Five-Year Survivors (12 in HX group and 13 in TX group)

	Age/Sex	Histology	Cirrhosis	TNM Stage	Recurrence	Survival
<b>HX Group</b>						
1	9/M	FL	NO	II	No	Alive after 11 years
2	63/M	NON-FL	NO	IV-A	No	Alive after 10 years
3	43/F	NON-FL	NO	III	No	Alive after 9 years
4	14/M	FL	NO	III	No	Alive after 8 years
5	40/F	NON-FL	NO	IV-A	Yes	Alive after 7 years
6	39/M	FL	NO	III	Yes	Died after 7 years
7	33/M	FL	NO	IV-A	No	Alive after 7 years
8	40/M	FL	NO	III	No	Alive after 7 years
9	41/F	NON-FL	NO	III	No	Alive after 6 years
10	65/F	NON-FL	NO	II	Yes	Died after 6 years
11	50/M	NON-FL	NO	II	No	Alive after 5 years
12	62/M	NON-FL	NO	II	No	Alive after 5 years
<b>TX Group</b>						
13	26/M	FL	NO	IV-A	No	Alive after 9 years
14	47/F	NON-FL	YES	II	No	Alive after 9 years
15	3/F	NON-FL	YES	II	No	Died after 7 years
16	7/F	NON-FL	YES	I	No	Alive after 8 years
17	22/F	NON-FL	YES	III	No	Alive after 8 years
18	23/F	FL	NO	IV-A	Yes	Died after 6 years
19	4/F	NON-FL	YES	I	No	Alive after 7 years
20	8/F	NON-FL	YES	II	No	Alive after 6 years
21	3/F	NON-FL	YES	III	No	Alive after 6 years
22	9/M	NON-FL	YES	II	No	Alive after 6 years
23	48/F	NON-FL	YES	III	No	Alive after 6 years
24	42/M	FL	YES	II	No	Alive after 5 years
25	33/F	NON-FL	NO	III	No	Died after 5 years

at 5 years) were similar to or even slightly better than those reported by others.<sup>17-30</sup> However our survival rates after hepatic resection for HCC in the cirrhotic liver were significantly lower than those reported from Asia, where early stages of HCC were removed from the cirrhotic liver by limited hepatic resection.<sup>21-30</sup> Our overall survival rates after liver transplantation for HCC in the cirrhotic liver (63.4% at 1 year, 42.9% at 3 years, and 40.7% at 5 years) were higher than those after hepatic resection for HCC in Asia.<sup>21-30</sup> Our survival rates after liver transplantation for HCC Of Stages I and II (early stages) in the cirrhotic liver were 80% at 1 year and 75% at 3 and 5 years (Table 6). A meaningful comparison could not be made in our own patients because there were only two patients with HCC of stage II in the cirrhotic liver who underwent subtotal hepatic resection. However these survival rates were similar to or even better than those after hepatic resection for most favorable lesions in Asia,<sup>26-30</sup> although the hepatic functions were worse in the liver transplantation group than in the resection group.

It is impractical and even fraudulent to recommend that all HCCs in the cirrhotic liver should be treated by liver transplantation. It is equally incorrect to exclude the patients with HCC from liver transplantation when the malignancy is confined to the liver. The treatment of choice for HCC confined to the liver is subtotal hepatic resection when it is anatomically and functionally feasible.

Liver transplantation is the treatment of choice for HCC confined to the liver when the hepatic functions are poor and/or the HCC cannot be removed by subtotal hepatic resection.

The HCC recurred in one half of the patients after hepatic resection and liver transplantation (Table 8). In the HCCs of stages II and III, the tumor recurrence was significantly higher after hepatic resection than liver transplantation. The fact may indicate either that the staging was less accurate in the hepatic resection group because only a removed part of the liver could be examined pathologically or that new HCC developed in the retained portion of the liver after hepatic resection. Nevertheless a relatively low incidence of tumor recurrence after liver transplantation for HCC of stages II and III were encouraging. On the other hand, two thirds of HCCs in stage IV-A recurred after hepatic resection and liver transplantation (Table 8).

Further improvement in survival rates will be achieved in some degree by reducing the incidence of early death from surgical complications, but the major progress will depend on nonsurgical anti-cancer therapy. For this series of our patients, organized plans of anti-cancer therapy before and/or after surgery were not available. Because the introduction of a novel immunosuppressive drug, FK 506, to our liver transplantation in mid 1989,<sup>34,35</sup> we have been exploring the possible beneficial effects of neoadju-

vant and adjuvant therapy for primary hepatobiliary malignancy. The improvement may be expected with this approach, particularly in HCCs of stages II and III after hepatic resection and in HCCs of stage IV-A after hepatic resection and liver transplantation, in which the tumor recurrence is frequent.

### References

- Starzl TE, Iwatsuki S, Van Thiel DH, et al. Evolution of liver transplantation. *Hepatology* 1982; 2:614-636.
- Iwatsuki S, Starzl TE, Todo S, et al. Experience in 1,000 liver transplants under cyclosporine-steroid therapy: a survival report. *Transplant Proc* 1988; 20(No 1, Suppl 1):498-504.
- Starzl TE, Demetris AJ, Van Thiel DH: Medical progress: liver transplantation. *N Engl J Med* 1989; I(321):1014-1022; II(321):1092-1099.
- Starzl TE (with the assistance CW Putnam). Experience in Hepatic Transplantation. Philadelphia: WB Saunders, 1969, pp 284-298.
- Iwatsuki S, Klintmalm GBG, Starzl TE. Total hepatectomy and liver replacement (orthotopic liver transplantation) for primary hepatic malignancy. *World J Surg* 1982; 6:81-85.
- Iwatsuki S, Gordon RD, Shaw BW Jr, et al. Role of liver transplantation in cancer therapy. *Ann Surg* 1985; 202:401-407.
- Yokoyama I, Todo S, Iwatsuki S, et al. Liver transplantation in the treatment of primary liver cancer. *Hepato Gastroenterol* 1990; 37:188-193.
- Calne RY. Liver transplantation. In Calne RY, Ed. *The Cambridge and King's College Hospital Experience*. London: Grune and Stratton, 1983, pp 306-311.
- O'Grady JA, Polson RJ, Rolles K, et al. Liver transplantation for malignant disease. Results in 93 consecutive patients. *Ann Surg* 1988; 207:373-379.
- Pichlmayr R, Ringe B, Wittekind C, et al. Liver grafting for malignant tumors. *Transplant Proc* 1989; 21:2403-2405.
- Ringe B, Wittekind C, Bechstein WO, et al. The role of liver transplantation in hepatobiliary malignancy. *Ann Surg* 1989; 209:88-98.
- Funovics JM, Fritsch A, Herbst F, et al. Primary hepatic cancer—the role of limited resection and total hepatectomy with orthotopic liver replacement. *Hepato-Gastroenterol* 1988; 35:316-320.
- Belli L, Romani F, Belli LS, et al. Reappraisal of surgical treatment of small hepatocellular carcinomas in cirrhosis: Clinicopathological study of resection or transplantation. *Dig Dis Sci* 1989; 10:1571-1575.
- Otte G, Heuschen UA, Hofmann WJ, et al. Primary hepatic malignancies: resection or liver transplantation? *Eur J Surg Oncol* 1990; 16:346-351.
- Ismail T, Angrisani L, Gunson BK, et al. Primary hepatic malignancy: the role of liver transplantation. *Br J Surg* 1990; 77:983-987.
- Iwatsuki S, Starzl TE. Personal experience with 411 hepatic resections. *Ann Surg* 1988; 208:421-434.
- Fortner JG, Silva JS, Golbey RB, et al. Multivariate analysis of a personal series of 247 consecutive patients with liver metastases from colorectal cancer. I. Treatment by hepatic resection. *Ann Surg* 1984; 199:306-316.
- Bismuth H, Houssin D, Ornowski J, et al. Liver resection in cirrhotic patients: a Western experience. *World J Surg* 1986; 10:311-317.
- Nagorney DM, van Heerden JA, Elstrup DM, et al. Primary hepatic malignancy: surgical management and determinants of survival. *Surgery* 1989; 106:740-749.
- Franco D, Capusotti L, Smadja C, et al. Resection of hepatocellular carcinomas. Results in 72 European patients with cirrhosis. *Gastroenterology* 1990; 98:733-738.
- Lin TY, Chen KM, Chen CC. Role of surgery in the treatment of primary carcinoma of the liver: a 21-year experience. *Br J Surg* 1987; 74:839-842.
- Hsu HZ, Wu TT, Wu MZ, et al. Tumour invasiveness and prognosis in resected hepatocellular carcinoma. Clinical and pathogenetic implications. *Cancer* 1988; 61:2095.
- Chen MF, Hwang TL, Jeng LBB, et al. Hepatic resection in 120 patients with hepatocellular carcinoma. *Arch Surg* 1989; 124:1025.
- Tang ZY, Yu YQ, Zhou XD, et al. Surgery of small hepatocellular carcinoma—analysis of 144 cases. *Cancer* 1989; 64:536.
- Lai ECS, Ng IOL, Ng MMT, et al. Long-term results of resection for large hepatocellular carcinoma: a multivariate analysis of clinicopathological features. *Hepatology* 1990; 11:815.
- Nagasue N, Yukaya K, Ogawa Y, et al. Clinical experience with 118 hepatic resections for hepatocellular carcinoma. *Surgery* 1986; 99:694.
- Nagao T, Goto S, Kawano N, et al. Hepatic resection for hepatocellular carcinoma: clinical features and long-term prognosis. *Ann Surg* 1987; 205:33.
- Ohnishi K, Tanabe Y, Ryu M, et al. Prognosis of hepatocellular carcinoma smaller than 5 cm in relation to treatment: study of 100 patients. *Hepatology* 1987; 7:1285.
- Yamanaka N, Okamoto E, Toyosaka A, et al. Prognostic factors after hepatectomy for hepatocellular carcinoma. *Cancer* 1990; 65:1104.
- Nonami T, Isshiki K, Katoh H, et al. The potential role of post-operative hepatic artery chemotherapy in patients with high-risk hepatomas. *Ann Surg* (In press).
- Hermanek P, Sobin LH, eds. *TNM Classification of Malignant Tumors, Fourth, Fully Revised Edition*. Berlin: Springer-Verlag, 1987, pp 53-55.
- American Joint Committee on Cancer. *Manual for Staging of Cancer, 3rd Edition*. Philadelphia: JB Lippincott, 1987, pp 87-92.
- Shibata J, Fujiyama S, Sato T, et al. Hepatic arterial injection chemotherapy with cisplatin suspended in an oil lymphographic agent for hepatocellular carcinoma. *Cancer* 1989; 64:1586-1594.
- Starzl TE, Todo S, Fung J, et al. FK 506 for human liver, kidney and pancreas transplantation. *Lancet* 1989; ii:1000-1004.
- Todo S, Fung JJ, Starzl TE, et al. Liver, kidney, and thoracic organ transplantation under FK 506. *Ann Surg* 1990; 212:295-305.

### DISCUSSION

DR. RONALD W. BUSUTTIL (Los Angeles, California): Dr. Iwatsuki and colleagues have presented a comparative analysis of subtotal hepatic resection *versus* liver transplantation for hepatocellular carcinoma according to the TNM (tumor, nodes, and metastases) classification. Additionally they have evaluated other prognostic factors that might influence the outcome of these patients.

These data strongly support the tenet that liver transplantation plays an important role in the treatment of selected patients with hepatocellular carcinoma that is confined to the liver and is not amenable to subtotal resection. Moreover transplantation is superior to resection in patients with cirrhosis, because in this condition the tumor is most often multifocal.

To put this paper into perspective, however, I believe it is important to view it *vis-a-vis* a collective series of 452 patients treated with liver

transplantation for hepatocellular carcinoma that has been previously reported.

May I have that slide, please? As shown here, the 2- and 3-year survival in this large group of patients is approximately 30%, and the 5-year survival is between 20% and 25%. The data presented today by Dr. Iwatsuki represent a measurable improvement over this, with a 40% to 50% survival at 2 to 3 years and a 36% survival at 5 years.

What factors have accounted for this benefit? The first that comes to mind is that all of the cases reported today were done in a modern area of liver replacement in which cyclosporine was the mainstay of immunosuppression, and many of the technical and management refinements of liver transplantation have been codified. Patient selection also could play a role.

This report includes a series of tumors that may have a more favorable prognosis: namely, fibrolamellar variant, 10 cases, although as mentioned, several of these were of the stage 4A variety; and early lesions,